One of the most promising novel coronavirus vaccine candidates might complete the Phase 3 stage of clinical trials as soon as next month, and the companies behind it will seek immediate FDA approval if the drug is deemed safe and effective. It’s the BNT162b2 candidate from Pfizer and BioNTech that’s currently in Phase 3 trials …
In a significant coronavirus vaccine update, Pfizer and BioNTech announced additional details about their experimental drug that has just started Phase 2/3 testing. The two companies revealed critical results for a group of elderly volunteers who weren’t previously addressed. The elderly are most at risk of developing COVID-19 complications. Pfizer and BioNTech say that volunteers …
A second coronavirus vaccine trial has entered the final stage of testing, and the research could be finalized as soon as October. One of the BioNTech/Pfizer vaccine candidates that were studied in preclinical and Phase 1/2 clinical trials has advanced to Phase 2/3. it will be tested on 30,000 participants at 120 sites around the …
The latest coronavirus vaccine development update comes from the US government, which inked a new deal for a promising vaccine made by BioNTech and Pfizer. The government pledged nearly $2 billion to secure 100 million doses of the experimental drug, assuming the vaccine candidate clears the final stage of clinical trials and receives the required …
Coronavirus vaccine research is moving along well, with another candidate showing promising results at preventing the COVID-19 infection. Pfizer’s CEO Albert Bourla said in an interview that the FDA could approve the BioNTech mRNA vaccine as soon as October, assuming Phase 3 of the trial goes well. Pfizer is already investing more than $1 billion …
Another coronavirus vaccine candidate has shown promising results in a Phase 1/2 trial conducted in the US. An mRNA experimental drug made by BioNTech, which partnered with Pfizer for the development of the drug, proved it can deliver the neutralizing antibodies that would be able to block the coronavirus and prevent infection. According to the …
Another potential coronavirus vaccine might be available this fall. Pfizer said the candidate it’s developing with BioNTech could be ready by October if everything goes well. There’s no guarantee that any of these vaccines will work, and several logistic challenges have to be addressed before mass immunization campaigns can be conducted. The development of vaccines …
German biopharmaceutical company BioNTech partnered with Pfizer on the development of an mRNA vaccine for the novel coronavirus. Their product reached the clinical phase trial stage, with Phase 1/2 testing already underway in Germany and the US. The first American volunteers will soon enroll in the trial, and the two companies say they may be …
A new coronavirus vaccine candidate from Germany has entered human trials, and it might be ready for emergency use as soon as this fall. Vaccine candidate BNT162 was administered to volunteers in Germany, although healthy American adults will also be included in the trial. BioNTech is working with Pfizer on the drug that has the …
Pfizer has a promising drug in development that targets the novel coronavirus’s ability to replicate. The new drug could help save patients experiencing mild-to-moderate COVID-19 cases, but extensive human testing is still needed. The pharmaceutical giant is also working on adapting additional drugs for severe COVID-19 cases, as well as four distinct vaccine candidates for …
